论文部分内容阅读
为评价血液稀释疗法(HD)对急性缺血性卒中(AIS)的长期疗效及 HD 的安全性,对102例 AIS 患者作随机对照研究,52例为血疗组(HP),50例为对照组(CP),两组平均年龄为73(51～92)岁。结果:(1)两组死亡率无显著差异,早期死亡不受 HD 影响,与过去报道相同。卒中后一年,二组各有16/52例(31%)与20/50例(40%)死亡,后期死亡多为心原性;(2)持久神经功能缺失在 HP 卒中后一年,定向、言语和运动功能率乱较 HP 明显减少,存活病人
To evaluate the long-term efficacy of hemodilution (HD) for acute ischemic stroke (AIS) and the safety of HD, a randomized controlled study of 102 patients with AIS was conducted. Fifty-two patients were treated with hemo-therapy (HP) and 50 as control Group (CP), the average age of both groups was 73 (51 ~ 92) years old. Results: (1) There was no significant difference in mortality between the two groups. Early death was not affected by HD, the same as in the past. One year after stroke, 16/52 (31%) and 20/50 (40%) deaths occurred in each of the two groups, with most of the subsequent deaths being cardiogenic. (2) Persistent loss of neurological function One year after stroke, Orientation, speech and motor function disorder significantly reduced compared with HP, surviving patients